MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock
$150,000K
Proceeds from issuance of
common stock upon...
$22,500K
Proceeds from exercise of
warrants and options
$25K
Net cash provided by
financing activities
$161,949K
(138.07%↑ Y/Y)
Canceled cashflow
$10,576K
Net (decrease)
increase in cash and cash...
-$8,594K
(-110.24%↓ Y/Y)
Canceled cashflow
$161,949K
Stock-based compensation
expense
$3,666K
(17.69%↑ Y/Y)
Prepaid expenses and
other assets
-$1,697K
(-6.73%↓ Y/Y)
Accounts payable
$388K
(-20.49%↓ Y/Y)
Other liabilities
$184K
Depreciation expense
$20K
(-28.57%↓ Y/Y)
Payment of issuance
costs associated with...
$10,565K
(51.67%↑ Y/Y)
Taxes paid related to
net share...
$11K
(-38.89%↓ Y/Y)
Net cash (used in)
provided by investing...
-$147,841K
(-507.40%↓ Y/Y)
Net cash used in
operating activities
-$22,702K
(-11.20%↓ Y/Y)
Canceled cashflow
$5,955K
Purchase of
available-for-sale securities
$147,841K
Net loss
-$23,331K
(13.28%↑ Y/Y)
Accrued liabilities
-$4,285K
(-384.15%↓ Y/Y)
Accretion of debt discount
on...
$1,041K
(333.75%↑ Y/Y)
Back
Back
Cash Flow
Forte Biosciences, Inc. (FBRX)
Forte Biosciences, Inc. (FBRX)
source: myfinsight.com